Harvard Medical School, 1986, MD
Harvard Graduate School of Arts and Sciences, 1986, PhD
Dr. Becker is pursuing several areas of translational research investigation, including 1) the mechanism of adhesion mediated chemotherapy resistance in acute myeloid leukemia and 2) hematopoietic stem cell gene therapy for an inherited disorder of DNA repair, Fanconi anemia, 3) application of precision medicine to hematologic malignancies with incorporation of genomic analysis, gene expression analysis, and in vitro high throughput drug sensitivity data to optimize treatment.
Optimizing therapy of hematological malignancies.
Gene therapy for inherited stem cell disorders.
Clinical trials in acute myeloid leukemia and multiple myeloma.
2097 Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)
2521 A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
7910 Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
9226 Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data
UW13037 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia
UW14053 A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy
UW14070 A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia
UW15075 An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma